| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2839895 | Clínica e Investigación en Arteriosclerosis | 2011 | 8 Pages |
Abstract
Our results indicate that, in addition to its lipid lowering activity, ezetimibe is able to inhibit the process of adhesion and migration of monocytes in vitro. Blocking of the p44/p42ERK1/2 MAPK signalling pathway seems to play a role in this anti-inflammatory effect.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Physiology
Authors
Paloma Muñoz-Pacheco, Adriana Ortega-Hernández, Arturo Fernández-Cruz, Dulcenombre Gómez-Garre,